Oral piritrexim, an effective treatment for metastatic urothelial cancer.

Piritrexim is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells rapidly by passive diffusion, cannot be polyglutamated, and is as effective as methotrexate in inhibiting DHFR. Bioavailability after oral dosing is approximately 75%. We performed a phase II study wit...

Descripción completa

Detalles Bibliográficos
Autores principales: de Wit, R., Kaye, S. B., Roberts, J. T., Stoter, G., Scott, J., Verweij, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968166/
https://www.ncbi.nlm.nih.gov/pubmed/8431372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968166/
https://www.ncbi.nlm.nih.gov/pubmed/8431372

Ejemplares similares